[Phosphocalcium metabolism in patients with calcified valvular bioprosthesis]

Presse Med. 1993 Apr 17;22(14):667-70.
[Article in French]

Abstract

Calcium and gla-protein content are increased in the calcifications of cardiac bioprostheses. Such calcifications are more frequent during growth, pregnancy and renal failure when bone gla-protein levels are elevated. We investigated whether bone gla-protein and other markers of calcium metabolism play a role in bioprostheses calcifications. Forty-seven patients were separated into 2 groups according to the presence (group A, n = 9) or absence (group B, n = 38) of bioprostheses calcifications, as assessed by echo-doppler and surgery. Plasma levels of calcium, phosphorus, magnesium, creatinine and alkaline phosphatases were measured by standard laboratory methods, parathormone and those of bone gla-protein by specific radioimmunoassays. Results (mean +/- SEM) were compared (group A versus group B, P < 0.01) using Student's test and one-factor variance analysis (ANOVA). Age was similar in both group (53 +/- 12.9 vs 50 +/- 12.3 yrs), whereas duration of implant was greater in group A (104 +/- 12.4 vs 66 +/- 6.5 months, P < 0.01). No statistically significant difference was found between group A and B concerning biochemical and/or hormonal markers of calcium metabolism. These negative results merit to be discussed, and further studies will be needed to explore the potential role of circulating bone gla-protein in bioprostheses calcifications.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Aortic Valve
  • Bioprosthesis / adverse effects*
  • Calcinosis / etiology
  • Calcinosis / metabolism*
  • Calcium / metabolism*
  • Female
  • Heart Valve Prosthesis / adverse effects*
  • Humans
  • Male
  • Middle Aged
  • Mitral Valve
  • Phosphorus / metabolism*
  • Prosthesis Failure

Substances

  • Phosphorus
  • Calcium